首頁 產業/市場分類 出版商一覽 Email 通知 GII媒體代理會議 公司簡介 聯絡我們
- English Japanese Korean
首頁 > 市場調查報告書 > 製藥 > 神經疾病 > 美國多發性硬化症市場
產業/市場分類
製藥 (4495)
肥胖症治療 (48)
非專利藥 (117)
疫苗 (168)
神經疾病 (175)
骨頭疾病治療 (41)
動物用醫藥 (18)
處方藥 (89)
規章 (107)
感染疾病 (318)
精神病 (80)
製藥企業 (506)
糖尿病 (157)
癌症 (838)
藥物開發 (1275)
DDS (173)
OTC 非處方藥 (147)
市場調查報告書

美國多發性硬化症市場

U.S. Multiple Sclerosis Markets

出版商 Frost & Sullivan
出版日期 2007年09月 商品編碼 56326
內容資訊 英文 77 Pages
價格
US $ 6000 Web Access (Regional License)
US $ 6500 Hard Copy & Web Access (Regional License)


美國多發性硬化症市場 是由出版商Frost & Sullivan在2007年09月所出版的。 這份英文市場調查報告書包含77 Pages 價格從美金6000起跳。

目錄

Abstract

This research service provides revenue forecasts, market shares, projected prevalence and treated populations, market trends, and existing and emerging therapeutics. There is a competitive and product analysis of the major market participants and products with competitive metrics for major and emerging companies.

Table of Contents

1. EXECUTIVE SUMMARY

Executive Summary

  • Introduction

2. MARKET INTRODUCTION

Introduction

  • Multiple Sclerosis
  • Scope and Segmentation
  • Research Methodology

Disease Overview

  • Causes of Multiple Sclerosis
  • Classification of Multiple Sclerosis
  • Treatment Options

Market Overview

  • Market Engineering Measurements
  • Market Trends

3. MARKET ANALYSIS

Product Analysis

  • Interferons
  • Copaxone
  • Tysabri
  • Novantrone
  • Pipeline Drugs

Patient Forecasts

  • Total Patient Forecasts
  • Patient Forecast by Product

Revenue Forecasts

  • Total Market Revenue Forecasts
  • Revenue Forecasts by Product

Competitive Analysis

  • Competitive Structure
  • Company Market Share

Competitve Metrics

  • Methodology and Metrics
  • Biogen Idec
  • Teva Pharmaceuticals
  • EMD Serono
  • Bayer Schering Pharma
  • Emerging Companies

4. DECISION SUPPORT DATABASES

Demographic Indicators

  • Total Population

Market Indicators

  • World Multiple Sclerosis Prevalence
  • U.S. Multiple Sclerosis Prevalence
  • U.S. Multiple Sclerosis Incidence
  • Pharmaceutical R&D Expenditure
Back to Top